Boston Scientific receives CE Mark for Rebel stent system

Boston Scientific has been granted European CE Mark approval for a new bare metal stent for the treatment of coronary artery disease.

The next-generation Rebel platinum chromium coronary stent system offers physicians the same stent platform as the Promus Premier drug-eluting stent, but without the use of the everolimus drug.

It  features unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, while improving axial strength and deliverability. Additionally, its enhanced low-profile delivery system features a shorter, more visible tip, a dual-layer balloon and an inner lumen catheter designed to facilitate precise delivery.

The product launch will provide a new option to patients who are unable to benefit from the use of drug-eluting stent therapy.

Kevin Ballinger, president of interventional cardiology at Boston Scientific, said: "Boston Scientific is committed to advancing cardiology and providing the best treatment options for all patients with coronary artery disease. This includes innovating and improving the performance of bare metal stent technology to enhance patient outcomes."

This comes after the firm received CE Mark approval for the use of its WallFlex oesophageal fully-covered stent as a means for treating refractory benign oesophageal strictures last month.